AlphaYou
Overview
Smart money at a glance
Filings to Sep 27, 2026No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- $0No open-market trades
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, latest quarter
- NoneNo large changes
- Federal contractsUSAspending.gov, last 12 months
- No awardsNone on record
Key stats
Fundamentals Sep 27- Open
- $1.84
- 52-wk high
- $20.99
- High
- $2.39
- 52-wk low
- $1.58
- Low
- $1.62
- Prev close
- $1.77
- Mkt cap
- $28.6M
- Volume
- 425.7K
- Beta
- 1.17
- P/B
- 2.8x
- Profit margin
- +0.0%
- Op margin
- +0.0%
- ROE
- -59.3%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about RNAZ filings
Are insiders buying or selling Transcode Therapeutics Inc (RNAZ) stock?
Neither. Transcode Therapeutics Inc (RNAZ) insiders filed no open-market purchases or sales in the 90 days to Sep 27, 2026, according to SEC Form 4 filings.
Which members of Congress have traded RNAZ recently?
None. No member of Congress disclosed a RNAZ trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this RNAZ smart-money data?
This summary uses filings available on Sep 27, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
1 fund holds a position.
How top traders are positioned
No tracked top-trader positions in RNAZ right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Results versus expectations
No reported figure for the latest quarter.
Our data provider never published one, so there is no beat-or-miss to show. The company's own release is above where we have it.
Reports Nov 13, 2026, in 47 days
Financials
Is the business strong?
This company is running thin margins.
- Net margin
- 0.0%
- Market cap
- $29M
Valuation
- P/B2.83
Quality
- Operating margin0.0%
- ROE-59.3%
- ROA-19.9%
Growth
- Beta1.17
Technicals
Price structure
This stock is under pressure.
Trend
Under pressure
0 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace